Calu-3 cells

/Tag:Calu-3 cells

Development of a Size-dependent Aerosol Deposition Model Utilising Human Airway Epithelial Cells for Evaluating Aerosol Drug Delivery

Daniel Cooney, Masha Kazantseva and Anthony J. Hickey

Aerosol delivery to the airways of the human respiratory tract, followed by absorption, constitutes an alternative route of administration for compounds unsuitable for delivery by conventional oral and parenteral routes. The target for aerosol drug delivery is the airways epithelium, i.e. tracheal, bronchial, bronchiolar and alveolar cells, which become the site of drug deposition. These epithelial layers also serve as a barrier to the penetration of inhaled material. An in vitro model for aerosol deposition and transport across epithelia in the human airways may be a good predictor of in vivo disposition. The present preliminary studies begin an investigation that blends the dynamics of aerosol delivery and the basis of an in vitro simulated lung model to evaluate the transport properties of a series of molecular weight marker compounds across human-derived bronchiolar epithelial cell monolayers. An Andersen viable cascade impactor was used as a delivery apparatus for the deposition of size-segregated particles onto monolayers of small airway epithelial cells and Calu-3 cells. It was shown that these cell layers can withstand placement in the impactor, and that permeability can be tested subsequent to removal from the impactor.
You need to register (for free) to download this article. Please log in/register here.

The Pharmaceutical Aerosol Deposition Device On Cell Cultures (PADDOCC) In Vitro System: Design and Experimental Protocol

Stephanie Hein, Michael Bur, Tobias Kolb, Bernhard Muellinger, Ulrich F. Schaefer and Claus-Michael Lehr

The development of aerosol medicines typically involves numerous tests on animals, due to the lack of adequate in vitro models. A new in vitro method for testing pharmaceutical aerosol formulations on cell cultures was developed, consisting of an aerosolisation unit fitting a commercial dry powder inhaler (HandiHaler®, Boehringer Ingelheim, Germany), an air-flow control unit (Akita®, Activaero, Germany) and a custom-made sedimentation chamber. This chamber holds three Snapwell® inserts with monolayers of pulmonary epithelial cells. The whole set-up, referred to as the Pharmaceutical Aerosol Deposition Device On Cell Cultures (PADDOCC) system, aims to mimic the complete process of aerosol drug delivery, encompassing aerosol generation, aerosol deposition onto pulmonary epithelial cells and subsequent drug transport across this biological barrier, to facilitate the investigation of new aerosol formulations in the early stages of development. We describe here, the development of the design and the protocol for this device. By testing aerosol formulations of budesonide and salbutamol sulphate, respectively, reproducible deposition of aerosol particles on, and the integrity of, the pulmonary cell monolayer could be demonstrated.
You need to register (for free) to download this article. Please log in/register here.